Precision Medicine in Oncology®

ASCO has endorsed the CAP/IASLC/AMP guideline on molecular testing for patients with lung cancer, which recommends EGFR and ALK testing for all patients with lung adenocarcinoma or mixed histology with an adenocarcinoma component.

Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.

The prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Numerous epidemiological factors affect the likelihood of developing breast and ovarian cancer, but no other predictor is as powerful as an inherited mutation in BRCA1 or BRCA2, genes involved in both tumor suppression and DNA repair.